核苷酸切除修复与抗癌化疗。
Nucleotide excision repair and anti-cancer chemotherapy.
机构信息
Division of Clinical Sciences, National Cancer Institute, Building 10, Room 12N226, Bethesda, MD, 20892, U.S.A. E-mail,
出版信息
Cytotechnology. 1998 Sep;27(1-3):187-201. doi: 10.1023/A:1008016922425.
Abstract
DNA repair is an important effector of anti-cancer drug resistance. In recent years, it has become apparent that DNA repair is an extremely complex process. Processes within DNA repair that may contribute to one or more drug resistance phenotypes include; O-6-alkyltransferase activity, base excision repair, mismatch repair, nucleotide excision repair, and gene specific repair. Clearly, several of these processes may show increased activity within any single cell, or tumor, at any one time. This review attempts to touch briefly upon the question of the distinctions between each of these specific pathways; and then seeks to expand on nucleotide excision repair as a possible effector of cellular and clinical resistance to platinum-based anticancer therapy.
摘要
DNA 修复是抗肿瘤药物耐药性的重要效应因子。近年来，人们已经明显认识到 DNA 修复是一个极其复杂的过程。在 DNA 修复过程中，可能导致一种或多种耐药表型的过程包括：O-6-烷基转移酶活性、碱基切除修复、错配修复、核苷酸切除修复和基因特异性修复。显然，在任何一个时间点，在单个细胞或肿瘤中，其中几种过程都可能表现出活性增强。这篇综述简要地探讨了这些特定途径之间的区别问题；然后探讨了核苷酸切除修复作为细胞和临床对铂类抗癌治疗耐药性的一种可能效应因子。
相似文献
1
Nucleotide excision repair and anti-cancer chemotherapy.
Cytotechnology. 1998 Sep;27(1-3):187-201. doi: 10.1023/A:1008016922425.
2
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.
Cancer Treat Rev. 1998 Oct;24(5):331-44. doi: 10.1016/s0305-7372(98)90056-1.
3
Platinum resistance: the role of DNA repair pathways.
Clin Cancer Res. 2008 Mar 1;14(5):1291-5. doi: 10.1158/1078-0432.CCR-07-2238.
4
5
Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
Mol Pharmacol. 2008 Jul;74(1):82-91. doi: 10.1124/mol.107.041988. Epub 2008 Apr 22.
6
Genome-wide single-nucleotide resolution of oxaliplatin-DNA adduct repair in drug-sensitive and -resistant colorectal cancer cell lines.
J Biol Chem. 2020 May 29;295(22):7584-7594. doi: 10.1074/jbc.RA120.013347. Epub 2020 Apr 16.
7
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas.
DNA Repair (Amst). 2019 Jun;78:128-141. doi: 10.1016/j.dnarep.2019.04.007. Epub 2019 Apr 15.
8
Nucleotide excision repair from site-specifically platinum-modified nucleosomes.
Biochemistry. 2003 Jun 10;42(22):6747-53. doi: 10.1021/bi034264k.
9
Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes.
Chem Biodivers. 2010 Mar;7(3):543-66. doi: 10.1002/cbdv.200800340.
10
Alkylation damage in DNA and RNA--repair mechanisms and medical significance.
DNA Repair (Amst). 2004 Nov 2;3(11):1389-407. doi: 10.1016/j.dnarep.2004.05.004.
引用本文的文献
1
Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer.
Int J Med Sci. 2017 Nov 2;14(13):1410-1417. doi: 10.7150/ijms.21938. eCollection 2017.
2
Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance.
Oncol Rep. 2017 Apr;37(4):1989-1997. doi: 10.3892/or.2017.5443. Epub 2017 Feb 14.
3
A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.
Int J Colorectal Dis. 2015 Sep;30(9):1173-83. doi: 10.1007/s00384-015-2273-z. Epub 2015 Jun 9.
4
Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
BMC Gastroenterol. 2014 Aug 29;14:154. doi: 10.1186/1471-230X-14-154.
5
β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK.
Int J Oncol. 2013 Sep;43(3):721-8. doi: 10.3892/ijo.2013.1996. Epub 2013 Jun 28.
6
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
Clin Genitourin Cancer. 2013 Sep;11(3):229-37. doi: 10.1016/j.clgc.2013.04.007. Epub 2013 May 17.
7
Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?
BMJ Open. 2013 Jan 3;3(1):e002030. doi: 10.1136/bmjopen-2012-002030.
8
Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.
Cancer Res. 2012 Feb 1;72(3):790-800. doi: 10.1158/0008-5472.CAN-11-3151. Epub 2011 Dec 16.
9
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.
Mol Cancer Ther. 2008 May;7(5):1246-50. doi: 10.1158/1535-7163.MCT-07-2206.
10
New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3611-6. doi: 10.1073/pnas.0737293100. Epub 2003 Mar 24.
本文引用的文献
1
Expression of an alternatively spliced ercc1 messenger-RNA species, is related to reduced DNA-repair efficiency in human T-lymphocytes.
Oncol Rep. 1995 Mar;2(2):209-14. doi: 10.3892/or.2.2.209.
2
Demonstration of a polymorphism in the gene ERCC1 by two DNA sequencing methods.
Oncol Rep. 1997 Sep-Oct;4(5):905-7. doi: 10.3892/or.4.5.905.
3
Platinum-DNA adduct in head and neck-cancer patients receiving Cisplatin and Carboplatin chemotherapy.
Int J Oncol. 1993 Aug;3(2):331-5. doi: 10.3892/ijo.3.2.331.
4
Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA.
Int J Oncol. 1996 Feb;8(2):313-7. doi: 10.3892/ijo.8.2.313.
5
Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.
Oncol Rep. 2000 Sep-Oct;7(5):1123-8. doi: 10.3892/or.7.5.1123.
6
Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines.
Int J Mol Med. 1998 Mar;1(3):617-20. doi: 10.3892/ijmm.1.3.617.
7
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
J Clin Oncol. 1998 Jan;16(1):309-16. doi: 10.1200/JCO.1998.16.1.309.
8
p53 tumor-suppressor gene: clues to molecular carcinogenesis.
J Cell Physiol. 1997 Nov;173(2):247-55. doi: 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A.
9
A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.
Mutat Res. 1997 Sep;382(1-2):13-20. doi: 10.1016/s1383-5726(97)00004-6.
10
Second pathway for completion of human DNA base excision-repair: reconstitution with purified proteins and requirement for DNase IV (FEN1).
EMBO J. 1997 Jun 2;16(11):3341-8. doi: 10.1093/emboj/16.11.3341.
Zotero 插件